Pharmacokinetics and anticoagulant effect of the direct thrombin inhibitor melagatran following subcutaneous administration to healthy young men
暂无分享,去创建一个
[1] Stig L Boström,et al. Effects of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, and dalteparin on the endogenous thrombin potential in venous blood from healthy male subjects , 2003, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[2] P. Petersen,et al. Ximelagatran versus warfarin forstroke prevention in patientswith nonvalvular atrial fibrillation , 2003 .
[3] J. Badimón,et al. Acute antithrombotic effects of ximelagatran, an oral direct thrombin inhibitor, and r‐hirudin in a human ex vivo model of arterial thrombosis , 2003, Journal of thrombosis and haemostasis : JTH.
[4] U. Bredberg,et al. Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[5] C. Mattsson,et al. Thrombin-induced platelet activation and its inhibition by anticoagulants with different modes of action , 2003, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[6] S. Schulman,et al. A randomized, controlled, dose‐guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I , 2003, Journal of thrombosis and haemostasis : JTH.
[7] B. Eriksson,et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial , 2002, The Lancet.
[8] C. Francis,et al. Ximelagatran versus Warfarin for the Prevention of Venous Thromboembolism after Total Knee Arthroplasty , 2002, Annals of Internal Medicine.
[9] J. Harenberg,et al. Influence of lepirudin, argatroban, and melagatran on prothrombin time and additional effect of oral anticoagulation. , 2002, Clinical chemistry.
[10] L. Lapidus,et al. Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis. , 2002, Thrombosis research.
[11] J. Harenberg,et al. Monitoring of Anticoagulant Effects of Direct Thrombin Inhibitors , 2002, Seminars in thrombosis and hemostasis.
[12] B. Eriksson,et al. Prophylaxis of venous thromboembolism with subcutaneous melagatran in total hip or total knee replacement: results from Phase II studies. , 2002, Thrombosis research.
[13] M. Wolzt,et al. Inhibition of Thrombin Generation by the Oral Direct Thrombin Inhibitor Ximelagatran in Shed Blood from Healthy Male Subjects , 2002, Thrombosis and Haemostasis.
[14] B. Eriksson,et al. A Dose-ranging Study of the Oral Direct Thrombin Inhibitor, Ximelagatran, and Its Subcutaneous Form, Melagatran, Compared with Dalteparin in the Prophylaxis of Thromboembolism after Hip or Knee Replacement: METHRO I , 2002, Thrombosis and Haemostasis.
[15] M. Ahnoff,et al. Determination of melagatran, a novel, direct thrombin inhibitor, in human plasma and urine by liquid chromatography-mass spectrometry. , 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[16] C. Colwell,et al. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study. , 2001, Archives of internal medicine.
[17] T. Lindahl,et al. Effect of Melagatran on Prothrombin Time Assays Depends on the Sensitivity of the Thromboplastin and the Final Dilution of the Plasma Sample , 2001, Thrombosis and Haemostasis.
[18] D. Gustafsson,et al. The effects of oral and intravenous direct thrombin inhibitors on the size of photochemically induced cortical infarction in rats. , 2001, Thrombosis research.
[19] A Abrahamsson,et al. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. , 2001, Thrombosis research.
[20] S. Carlsson,et al. Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat. , 1999, Thrombosis research.
[21] J. Stürzebecher,et al. Synthetic inhibitors of thrombin and factor Xa: from bench to bedside. , 1999, Thrombosis research.
[22] P. Held,et al. Pharmacokinetics and Pharmacodynamics of Melagatran, a Novel Synthetic LMW Thrombin Inhibitor, in Patients with Acute DVT , 1999, Thrombosis and Haemostasis.
[23] T. Saldeen,et al. Melagatran, a Low Molecular Weight Thrombin Inhibitor, Counteracts Endotoxin-induced Haemodynamic and Renal Dysfunctions in the Pig , 1998, Thrombosis and Haemostasis.
[24] J. Mehta,et al. Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery. , 1998, Journal of cardiovascular pharmacology.
[25] B. Eriksson,et al. Antithrombotic Effect of Two Low Molecular Weight Thrombin Inhibitors and a Low-Molecular Weight Heparin in a Caval Vein Thrombosis Model in the Rat , 1997, Thrombosis and Haemostasis.
[26] J. Deinum,et al. The Importance of Enzyme Inhibition Kinetics for the Effect of Thrombin Inhibitors in a Rat Model of Arterial Thrombosis , 1997, Thrombosis and Haemostasis.
[27] V. Tapson,et al. Management of venous thromboembolic disease. The impact of low-molecular-weight heparin. , 1995, Clinics in chest medicine.
[28] G. Claeson. Synthetic peptides and peptidomimetics as substrates and inhibitors of thrombin and other proteases in the blood coagulation system. , 1994, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[29] T. Barrowcliffe,et al. Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin iii and by gel filtration. , 1976, Thrombosis research.
[30] P. Petersen,et al. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study. , 2003, Journal of the American College of Cardiology.
[31] B. Eriksson,et al. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery. , 2002, Thrombosis and haemostasis.
[32] S. Pehrsson,et al. Effects of Melagatran, a New Low-molecular-weight Thrombin Inhibitor, on Thrombin and Fibrinolytic Enzymes , 1998, Thrombosis and Haemostasis.
[33] P. Owren,et al. The control of dicumarol therapy and the quantitative determination of prothrombin and proconvertin. , 1951, Scandinavian journal of clinical and laboratory investigation.